Publications
Characterization of a patient-derived variant of GPX4 for precision therapy. Nat Chem Biol. 18, 91-100
(2022) Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun. 13, 1891
(2022) Pharmacological inhibition of NT5C2 reverses genetic and non-genetic drivers of 6-MP resistance in acute lymphoblastic leukemia. Cancer Discov. 10.1158/2159-8290.CD-22-0010
(2022) Small-molecule allosteric inhibitors of GPX4. Cell Chem Biol. 10.1016/j.chembiol.2022.11.003
(2022) (2021)
(2017)